GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tonix Pharmaceuticals Holding Corp (LTS:0A4T) » Definitions » Total Equity

Tonix Pharmaceuticals Holding (LTS:0A4T) Total Equity : $42.10 Mil (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Tonix Pharmaceuticals Holding Total Equity?

Tonix Pharmaceuticals Holding's total equity for the quarter that ended in Jun. 2024 was $42.10 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Tonix Pharmaceuticals Holding Total Equity Historical Data

The historical data trend for Tonix Pharmaceuticals Holding's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tonix Pharmaceuticals Holding Total Equity Chart

Tonix Pharmaceuticals Holding Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.42 87.65 218.72 207.18 105.53

Tonix Pharmaceuticals Holding Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 140.46 120.83 105.53 108.14 42.10

Tonix Pharmaceuticals Holding Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Tonix Pharmaceuticals Holding's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=154.457-48.932
=105.53

Tonix Pharmaceuticals Holding's Total Equity for the quarter that ended in Jun. 2024 is calculated as

Total Equity=Total Assets(Q: Jun. 2024 )-Total Liabilities(Q: Jun. 2024 )
=70.307-28.204
=42.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tonix Pharmaceuticals Holding Total Equity Related Terms

Thank you for viewing the detailed overview of Tonix Pharmaceuticals Holding's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Tonix Pharmaceuticals Holding Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tonix Pharmaceuticals Holding Corp (LTS:0A4T) » Definitions » Total Equity
Comparable Companies
SNTI LABP LPCN ALZN OTLC GNPX PHGE MLCT VBLT MBIO OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
TNXP:USA
Address
26 Main Street, Suite 101, Chatham, NJ, USA, 07928
Website
https://www.tonixpharma.com
Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company focused on developing therapeutics and vaccines to treat and prevent human disease and alleviate suffering. its portfolio consists of the central nervous system, rare disease, immunology, and infectious disease product candidates. The CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. CNS product candidate is TNX-102 SL, a proprietary sublingual tablet formulation of cyclobenzaprine (CBP) designed for bedtime administration.

Tonix Pharmaceuticals Holding Headlines

No Headlines